Wenhua Du

Wenhua Du

Auto-generated profile, based on publicly available information

Wenhua Du

Department of Ultrasound, Sichuan Taikang Hospital, Chengdu, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2012 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
TLTao Li
Tao Li
GLGuancheng Liu
Guancheng Liu
JLJie Li
Jie Li
XWXiang Wang
Xiang Wang
QLQuanquan Liu
Quanquan Liu
WDWenhua Du
Wenhua Du

15 April 2014 in Military Medical Research
Verified
Journal Article
Open access
PDF file
ZWZheng-Gang Wang
Zheng-Gang Wang
HTHao Tan
Hao Tan
LZLianyang Zhang
Lianyang Zhang
DLDao-Cheng Liu
Dao-Cheng Liu
HXHua-Liang Xiao
Hua-Liang Xiao
WDWen-Hua Du
Wen-Hua Du
To investigate the effect of intra-abdominal volume increment (IAVI) on intra-abdominal hypertension (IAH) in the kidneys. Eight minipigs were successfully established as IAH models and were randomly divided into two groups: the IAVI group and the sham-operated group. The intravesicular pressure, inferior vena cava pressure and urine volume were measured before shock, 2 h after IAH, and 22 h after surgery, respectively. The following indices were measured: serum creatinine, urea nitrogen, renal cortical thickness, ratio of abdominal anteroposterior diameter/transverse diameter, renal thickness, diameter of the renal sinus and the wet/dry ratio of renal tissues. The intravesicular pressure (IVP) of the 8 minipig IAH models was calculated to be 21.16 ± 4.63 mmHg. There was a significant increase in the abdominal anteroposterior diameter/transverse diameter ratio. The minipigs in the IAVI group survived during the observational period, whereas 2 minipigs died at 18 h and 20 h in the sham-operated group. Twenty-two hours after surgery, the animals in the IAVI group displayed increased urinary volume (UV) and decreased Cr and Ur and remarkable decreases of VP and IVCP. After IAH, the renal cortical thickness and the renal thickness increased significantly. The renal wet/dry ratio in the sham-operated group was higher than that in the IAVI group. IAVI helps to control renal dysfunction after IAH, which may be related to lowering the intra-abdominal pressure, thus alleviating renal edema and blood stasis.

27 October 2025 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MGMingxia Gao
Mingxia Gao
CLChuan Lin
Chuan Lin
YLYanhua Li
Yanhua Li
LLLing Li
Ling Li
XCXiaoqiao Chen
Xiaoqiao Chen
QPQing Pan
Qing Pan
Evidence remains insufficient to clarify whether hyperglycemia or hyperlipidemia exerts a greater influence on the development of liver steatosis and fibrosis. Furthermore, it remains uncertain whether distinct glucose-lipid metabolic profiles are associated with an increased risk of these hepatic conditions. We used NHANES data to assess liver steatosis and fibrosis via Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM), then propensity-score weighted regression was used to access associations between seven glycolipid metabolic biomarkers and the two liver indices. Radar plots and network analysis were utilized to illustrate metabolic distribution patterns and delineate key metabolic signatures distinguishing four liver health phenotypes: Healthy Control, Steatotic Liver, Fibrotic Liver, and Combined Steatotic-Fibrotic Liver. Linear regression analyses were further conducted to compare the levels of steatosis and fibrosis across eight metabolic subgroups, categorized according to distinct combinations of dyslipidemia, dysglycemia, and insulin resistance. Lastly, a tree-based algorithm was employed to identify distinct glycolipid metabolic profiles associated with increased severity of hepatic steatosis and fibrosis. A total of 9698 individuals were included (mean age: 44.26 $$\:\pm\:$$ 20.80 years). Propensity score-weighted regression showed that TG, GLU, HbA1c, and HDL were significantly associated with both CAP and LSM, while TC and LDL were associated with CAP only. Radar plots and network analysis revealed that the steatosis-fibrosis group had the most adverse metabolic profile, with the lowest HDL, highest insulin, HbA1c, and GLU levels. TG and GLU consistently ranked as the top two central metabolic hubs across all liver groups, while HbA1c ranked third except in the steatotic-fibrotic group, where insulin resistance prevailed. Among subgroups with a single metabolic abnormality, CAP was highest in the insulin resistance (IR)-only group (B = 14.433, P < 0.001), followed by the dysglycemia-only group (B = 10.142, P < 0.001), and lowest in the dyslipidemia-only group. In IR-associated subgroups, CAP was significantly higher when IR co-occurred with dysglycemia (B = 57.393, P < 0.001) than with dyslipidemia (B = 53.635, P < 0.001). The triple abnormalities group exhibited the highest overall CAP (B = 79.811, P < 0.001) as well as the highest liver stiffness measurement (LSM) (B = 1.543, P < 0.001). Tree-based analysis further identified that CAP was highest in individuals with insulin ≥ 14.705 µU/mL and GLU ≥ 5.861 mmol/L, while LSM was highest in those with insulin between 17.1 and 28.205 µU/mL, HbA1c ≥ 6.15%, and GLU ≥ 7.861 mmol/L. Metabolic abnormalities related to hyperglycemia may be more closely associated with hepatic steatosis and fibrosis than those related to hyperlipidemia.